UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): ~~January~~March 829, 2010 (~~January~~March 415, 2010)

PROTEIN POLYMER TECHNOLOGIES, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware		000-19724		33-0311631
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

11494 Sorrento Valley Road, San Diego, CA		92121
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 558-6064

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

OnEffective ~~January~~March 415, 2010, ~~William~~Richard N.Adelson ~~Plamondon III,~~ resigned ~~from~~ his position as a member of the Board of Directors (the “Board”) of Protein Polymer Technologies, Inc. (the “Company”). Such resignation includes his positions as a member of both the Audit Committee and Compensation Committee of the Board of the Company. Mr. ~~Plamondon~~ Adelson’s resignation was not a the result of any known disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.

~~The~~Effective ~~Company~~March is15, ~~working~~2010, ~~diligently~~Allan toFarber ~~identify~~resigned his position as a ~~suitable~~member ~~individual~~of tothe ~~fill~~Board of the Company. Such resignation includes his positions as a member of ~~Board~~both ~~seat~~the ~~vacated~~Audit byCommittee and Compensation Committee of the Board of the Company. Mr. ~~Plamondon~~ Farber’s resignation was not the result of any known disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.

Effective March 15, 2010, Kerry L. Kuhn, M.D., resigned his position as a member of the Board of the Company. Such resignation includes his position as a member of the Compensation Committee of the Board of the Company. Dr. Kuhn’s resignation was not the result of any known disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.

The Company has not yet identified suitable individuals to fill the Board seats vacated by Mr. Adelson, Mr. Farber, and Dr. Kuhn.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PROTEIN POLYMER TECHNOLOGIES, INC.
Date: January 8, 2010	By:	/S/ JAMES B. MCCARTHY
Date: March 29, 2010	By:	/S/ JAMES B. MCCARTHY
		James B. McCarthy Interim Chief Executive Officer

Filing Compare · PROTEIN POLYMER TECHNOLOGIES INC